Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Public Citizen Calls For Investigation Into Collaboration Between FDA and Biogen Over New Alzheimer’s Drug December 15, 2020 Irvin Jackson Add Your Comments A government watchdog group is calling for an investigation into the U.S. Food and Drug Administration’s handling of a new Biogen Alzheimer’s disease drug, saying the agency was dangerously cozy with the drug manufacturer. In a December 9 letter (PDF) to the U.S. Department of Health and Human Services’ Office of Inspector General, Public Citizen called for the office to look into what it calls an “inappropriate close collaboration” with Biogen by FDA drug approval reviewers. According to the letter, the close relationship, which began before the company’s biologics license application (BLA) seeking approval for a proposed drug known as aducanumab, could have compromised the agency’s judgment. Aducanumab is a drug under development by Biogen as a potential Alzheimer’s disease treatment. It is an experimental recombinant human monoclonal antibody targeting amyloid-β multimers. Do You Know about… SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Do You Know About… SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Public Citizen indicates the pharmaceutical industry has tried 22 times over the past 20 years to pursue similar drugs for Alzheimer’s treatment, all of which have failed. The group says those drugs, like aducanumab, are based on an unproven “amyloid hypothesis” introduced in the early 1990s which rests on the premise that amyloid plaque deposits in the brain cause neuronal degeneration linked to Alzheimer’s disease. The letter indicates aducanumab is likely no different. In fact, Biogen and Eisai, which were working on the drug together, issued a press release in March 2019 announcing they were abandoning the phase 3 trials after an interim analysis found those trials were unlikely to show the drug actually worked. Development of the drug should have ended there, Public Citizen claims. Instead, the drug is up for approval with a glowing review from the FDA. According to Public Citizen, the review was the result of the FDA and Biogen working together to cherry-pick data from the clinical trials, despite the drug’s failure to perform. In October 2019, Biogen announced plans to seek approval of aducanumab for patients with early signs of Alzheimer’s disease after reportedly conducting new analyses of data from previous studies in cooperation with the FDA. Biogen applied for a BLA in July 2020, and on November 4, the FDA posted a briefing document for its Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee. “Disturbingly, the primary briefing document was a 139-page document written jointly by the FDA and Biogen,” Public Citizen notes. “Most of the primary briefing document content appears to have been written by Biogen.” The document revealed the FDA and Biogen had been working together since at least June 2019, following the company’s decision to abandon the Phase 3 trials, when the FDA told Biogen the best way to look at the earlier data was a “bilateral effort involving the Agency and sponsor”, according to the letter. However, it did not reveal that the agency’s lead statistical reviewer, Dr. Tristan Massie, had his own objections to the methodology being used to promote the drug as effective. “The totality of the data does not seem to provide sufficient evidence to support the efficacy of the high dose,” Massie wrote in his review. “There is much inconsistency and no replication.” That analysis did not find its way into the briefing documents provided by the FDA, according to Public Citizen. Public Citizen warns this represents an unprecedented, and dangerous, level of cooperation between the FDA and a drug manufacturer in order to get a drug, which has already been shown to be ineffective, onto the market. “Although we understand that it is not unusual for the FDA to meet with sponsors and provide advice regarding the development of drugs, the design of clinical trials, and the statistical analyses of trial data, among other things, the close collaboration that occurred between the agency and Biogen in conducting post hoc analyses of data from the aducanumab clinical trials is, to our knowledge, unprecedented,” the Public Citizen letter warns. “Typically, sponsors conduct their own detailed statistical analyses of clinical trial data supporting NDAs and BLAs, and the FDA then conducts its own independent analyses of the data following submission of these applications for approval. Such appropriate separation between the clinical trial data analyses conducted by the sponsor and those conducted by the FDA is critical to maintaining the independence and integrity of the FDA’s review of the data.” The letter calls for the Office of Inspector General to launch a formal investigation into that relationship, which Public Citizen says has dangerously compromised the independence and objectivity of FDA staff, including senior staff and clinical reviewers. The drug has not yet been approved for sale. Tags: Alzheimer's Disease, Biogen, Clinical Trials More Lawsuit Stories Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 July 8, 2025 Mead Johnson Must Face Enfamil NEC Lawsuit in Missouri State Court July 8, 2025 FanDuel Class Action Lawsuit Alleges Fantasy Games Constitute Illegal Sports Gambling July 8, 2025 1 Comments Karen December 15, 2020 People are desperate for an alzheimer treatment. The FDA’s responsibility is to protect Americans from unscrupulous drug dealers. Looks like they are not doing their job. When government works correctly, we are all better off for it. Cozying up to big pharma doesn’t protect citizens. Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermNameThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: yesterday) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025) Lawsuit Indicates Biozorb Side Effects Left Woman With Chronic Pain, Disfiguring Injuries (Posted: 2 days ago) A BioZorb side effects lawsuit indicates that a woman is suffering chronic pain and soreness after the tissue marker implant failed to absorb into her body as advertised. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (06/30/2025)Lawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025) Second Wave of Valsartan Cancer Lawsuits To Be Ready for Bellwether Trials by January 2026 (Posted: 2 days ago) A new schedule for a second wave of Valsartan cancer lawsuit bellwether trials hopes to have a case ready to go before a jury by January 2026. MORE ABOUT: VALSARTAN LAWSUITCourt Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases (05/28/2025)Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named (03/27/2025)Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master (03/04/2025)
Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: yesterday) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025)
Lawsuit Indicates Biozorb Side Effects Left Woman With Chronic Pain, Disfiguring Injuries (Posted: 2 days ago) A BioZorb side effects lawsuit indicates that a woman is suffering chronic pain and soreness after the tissue marker implant failed to absorb into her body as advertised. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (06/30/2025)Lawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025)
Second Wave of Valsartan Cancer Lawsuits To Be Ready for Bellwether Trials by January 2026 (Posted: 2 days ago) A new schedule for a second wave of Valsartan cancer lawsuit bellwether trials hopes to have a case ready to go before a jury by January 2026. MORE ABOUT: VALSARTAN LAWSUITCourt Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases (05/28/2025)Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named (03/27/2025)Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master (03/04/2025)